60210 Federal Register / Vol. 88, No. 168 / Thursday, August 31, 2023 / Notices 

other forms of information technology. 

OMB has approved this information 

collection for use through February 29, 

2024. DoD, GSA, and NASA propose 

that OMB extend its approval for use for 

three additional years beyond the 

current expiration date. 

DATES: DoD, GSA, and NASA will 

consider all comments received by 

October 30, 2023. 

ADDRESSES: DoD, GSA, and NASA 

invite interested persons to submit 

comments on this collection through 

https://www.regulations.gov and follow 

the instructions on the site. This website 

provides the ability to type short 

comments directly into the comment 

field or attach a file for lengthier 

comments. If there are difficulties 

submitting comments, contact the GSA 

Regulatory Secretariat Division at 202– 

501–4755 or GSARegSec@gsa.gov. 

Instructions: All items submitted 

must cite OMB Control No. 9000–0157, 

Architect-Engineer Qualifications (SF– 

330). Comments received generally will 

be posted without change to https://

www.regulations.gov, including any 

personal and/or business confidential 

information provided. To confirm 

receipt of your comment(s), please 

check www.regulations.gov, 

approximately two-to-three days after 

submission to verify posting. 

FOR FURTHER INFORMATION CONTACT: 

Zenaida Delgado, Procurement Analyst, 

at telephone 202–969–7207, or 

zenaida.delgado@gsa.gov. 

SUPPLEMENTARY INFORMATION: 

A. OMB Control Number, Title, and 

Any Associated Form(s) 

9000–0157, Architect-Engineer 

Qualifications, SF–330. 

B. Need and Uses 

This clearance covers the information 

that offerors must submit to comply 

with the following Federal Acquisition 

Regulation (FAR) requirement: 

Standard Form (SF) 330, ArchitectEngineer Qualifications. As specified in 

FAR 36.702(b), an architect-engineer 

firm must provide information about its 

qualifications for a specific contract 

when the contract amount is expected to 

exceed the simplified acquisition 

threshold (SAT). 

Part I—Contract-Specific 

Qualifications. The information on the 

form is reviewed by a selection panel 

composed of professionals and assists 

the panel in selecting the most qualified 

architect-engineer firm to perform the 

specific project. The form is designed to 

provide a uniform method for architectengineer firms to submit information on 

experience, personnel, and capabilities 

of the architect-engineer firm to perform 

along with information on the 

consultants they expect to collaborate 

with on the specific project. Part I of the 

SF 330 may be used when the contract 

amount is expected to be at or below the 

SAT, if the contracting officer 

determines that its use is appropriate. 

Part II—General Qualifications. The 

information obtained on this form is 

used to determine if a firm should be 

solicited for architect-engineer projects. 

Architect-engineer firms are encouraged 

to update the form annually. Part II of 

the SF 330 is used to obtain information 

from an architect-engineer firm about its 

general professional qualifications. 

The SF 330 accomplishes the 

following: 

• Expands essential information 

about qualifications and experience data 

including: 

❖ An organizational chart of all 

participating firms and key personnel. 

❖ For all key personnel, a description 

of their experience in 5 relevant 

projects. 

❖ A description of each example 

project performed by the project team 

(or some elements of the project team) 

and its relevance to the agency’s 

proposed contract. 

❖ A matrix of key personnel who 

participated in the example projects. 

This matrix graphically illustrates the 

degree to which the proposed key 

personnel have worked together before 

on similar projects. 

• Reflects current architect-engineer 

disciplines, experience types and 

technology. 

• Permits limited submission length 

thereby reducing costs for both the 

architect-engineer industry and the 

Government. Lengthy submissions do 

not necessarily lead to a better decision 

on the best-qualified firm. The proposed 

SF 330 indicates that agencies may limit 

the length of a firm’s submissions, either 

certain sections or the entire package. 

The Government’s right to impose such 

limitations was established in case law 

(Coffman Specialties, Inc., B–284546. 

N–284546/2, 2000 U.S. Comp. Gen. 

LEXIS 58, May 10, 2000). 

The contracting officer uses the 

information provided on the SF 330 to 

evaluate firms to select an architectengineer firm for a contract. 

C. Annual Burden 

Respondents: 682. 

Total Annual Responses: 2,728. 

Total Burden Hours: 79,112. 

Obtaining Copies: Requesters may 

obtain a copy of the information 

collection documents from the GSA 

Regulatory Secretariat Division by 

calling 202–501–4755 or emailing 

GSARegSec@gsa.gov. Please cite OMB 

Control No. 9000–0157, ArchitectEngineer Qualifications (SF–330). 

Janet Fry, 

Director, Federal Acquisition Policy Division, 

Office of Governmentwide Acquisition Policy, 

Office of Acquisition Policy, Office of 

Governmentwide Policy. 

[FR Doc. 2023–18843 Filed 8–30–23; 8:45 am] 

BILLING CODE 6820–EP–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Closed Meeting 

Pursuant to section 5 U.S.C. 1009(d), 

notice is hereby given of the following 

meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended, and the Determination of 

the Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, CDC, pursuant to Public Law 

92–463. The grant applications and the 

discussions could disclose confidential 

trade secrets or commercial property 

such as patentable material, and 

personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: Disease, 

Disability, and Injury Prevention and 

Control Special Emphasis Panel; (SEP)– 

RFA–OH–22–003, Occupational Safety 

and Health Training Project Grants. 

Date: November 30, 2023. 

Time: 1 p.m.–5 p.m., EST. 

Place: Video-Assisted Meeting. 

Agenda: To review and evaluate grant 

applications. 

FOR FURTHER INFORMATION CONTACT: 

Marilyn Ridenour, B.S.N., M.P.H., 

Scientific Review Official, Office of 

Extramural Programs, Centers for 

Disease Control and Prevention, 1095 

Willowdale Road, Morgantown, West 

Virginia 26505. Telephone: (304) 285– 

5879; Email: MRidenour@cdc.gov. 

The Director, Office of Strategic 

Business Initiatives, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 


ddrumheller on DSK120RN23PROD with NOTICES1
Federal Register / Vol. 88, No. 168 / Thursday, August 31, 2023 / Notices 60211 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Office of Strategic Business 

Initiatives, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2023–18806 Filed 8–30–23; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2023–N–0940] 

Agency Information Collection 

Activities; Submission for Office of 

Management and Budget Review; 

Comment Request; Food and Drug 

Administration Rapid Response 

Surveys 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice. 

SUMMARY: The Food and Drug 

Administration (FDA) is announcing 

that a proposed collection of 

information has been submitted to the 

Office of Management and Budget 

(OMB) for review and clearance under 

the Paperwork Reduction Act of 1995. 

DATES: Submit written comments 

(including recommendations) on the 

collection of information by October 2, 

2023. 

ADDRESSES: To ensure that comments on 

the information collection are received, 

OMB recommends that written 

comments be submitted to https://

www.reginfo.gov/public/do/PRAMain. 

Find this particular information 

collection by selecting ‘‘Currently under 

Review—Open for Public Comments’’ or 

by using the search function. The OMB 

control number for this information 

collection is 0910–0500. Also include 

the FDA docket number found in 

brackets in the heading of this 

document. 

FOR FURTHER INFORMATION CONTACT: 

JonnaLynn Capezzuto, Office of 

Operations, Food and Drug 

Administration, Three White Flint 

North, 10 a.m.–12 p.m., 11601 

Landsdown St., North Bethesda, MD 

20852, 301–796–3794, PRAStaff@

fda.hhs.gov. 

SUPPLEMENTARY INFORMATION: In 

compliance with 44 U.S.C. 3507, FDA 

has submitted the following proposed 

collection of information to OMB for 

review and clearance. 

Rapid Response Surveys 

OMB Control Number 0910–0500— 

Extension 

This generic information collection 

supports research conducted by FDA, as 

authorized under section 1003(d)(2) of 

the Federal Food, Drug, and Cosmetic 

Act (21 U.S.C. 393(d)(2)). 

FDA is requesting extension of OMB 

approval to conduct rapid response 

surveys (RRS). Through these surveys, 

FDA seeks to determine whether a 

problem impacts the public health and 

to quickly obtain vital information about 

risks and interventions. FDA will use 

the information gathered from these 

surveys to make quick turnaround 

decisions about safety problems or risk 

management solutions so the Agency 

may take appropriate public health 

action including dissemination of 

information as necessary. Participation 

in these surveys is voluntary. 

Respondents may include 

manufacturers and distributors of 

biologics, drugs, food, animal food and 

drugs, dietary supplements, food 

additives, cosmetics, medical devices, 

and tobacco products; distributors; 

sponsors and importers; consumers; 

healthcare professionals; hospitals; 

specialized medical facilities (e.g., 

cardiac surgery, obstetrics/gynecology 

services, pediatric services, etc.) and 

other user facilities including nursing 

homes, ambulatory surgical and 

outpatient diagnostic and treatment 

facilities when FDA must quickly 

determine whether or not a problem 

impacts the public health. Once FDA 

understands the need for additional 

surveillance data to address a potential 

public health hazard, the appropriate 

respondents will be identified for each 

unique RRS. 

In the Federal Register of April 20, 

2023 (88 FR 24423), FDA published a 

60-day notice requesting public 

comment on the proposed collection of 

information. We received one comment, 

which was generally supportive of 

FDA’s use of RRS. (Comment) The 

comment suggested that FDA 

‘‘authorize, develop, and implement a 

mechanism that provides States and the 

most local level of public health 

departments immediate notification and 

access to RRS results when the FDA 

issues a RRS wholly or partially in their 

areas of jurisdiction.’’ (Response) FDA 

already has in place mechanisms to 

share pertinent health information with 

State, local, and tribal authorities. We 

currently share aggregated data (without 

personally identifiable information) of 

hospital reporting RRS. However, FDA’s 

use of RRS has not recently developed 

data about potential safety problems or 

risk management solutions that would 

require development of a new 

mechanism for immediate notification 

and access to RRS results. For example, 

FDA used a RRS to identify and 

maintain a list of drugs essential for the 

care and management of hospitalized 

patients with COVID–19, particularly 

for ventilated patients in the intensive 

care units. FDA used the information to 

help to identify drugs that may be at risk 

of a regional or national shortage, and to 

help ensure these drugs remain 

available to meet the needs of our 

nation. FDA also used a RRS to engage 

stakeholders when developing the food 

safety surveillance sampling 

assignments. FDA shared information 

with key external stakeholders on the 

hot pepper and cucumber sampling 

assignments and garnered industry 

feedback through survey questions to 

ensure that sample collection is done as 

effectively and efficiently as possible. 

Neither of these surveys developed 

information that would require 

development of a new mechanism for 

immediate notification and access to 

RRS results. The latest update survey 

data from FDA can be found here: 

https://www.fda.gov/science-research/ 

fda-science-forum/fda-covid-19-criticalcare-drug-monitoring-survey-portalongoing-surveillance-critical-drugsrelated. Please also note that if you or 

your hospital stakeholders are 

experiencing a drug shortage and need 

assistance on how to obtain supply, 

please refer to the information at 

Drugshortages@fda.hhs.gov. FDA Drug 

Shortage Staff responds to all reports 

received on a daily basis. 

FDA estimates the burden of this 

collection of information as follows: 


ddrumheller on DSK120RN23PROD with NOTICES1